Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases

NCT04808752 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Almonertinib

Sponsor

Zhejiang Cancer Hospital

Collaborators

[object Object]